Vista Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 384463,
    "name": "Vista Pharma.",
    "stock_name": "Vista Pharma.",
    "full_name": "Vista Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/vista-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "6.53",
    "chg": -0.06,
    "chgp": "-0.91%",
    "dir": -1,
    "prev_price": "6.59",
    "mcapval": "40.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524711,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE427C01021",
    "curr_date": "Mar 13",
    "curr_time": "",
    "bse_nse_vol": "2.29 lacs",
    "exc_status": "Active",
    "traded_date": "Mar 13, 2026",
    "traded_date_str": "2026 03 13",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/vista-pharma-384463-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.5.71",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-ltd-stock-falls-to-52-week-low-of-rs571-3879799",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_priceRelatedfactors_3879799.png",
        "date": "2026-03-09 11:27:42",
        "description": "Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3873130",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_mojoScore_3873130.png",
        "date": "2026-03-05 10:10:20",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.6.05",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-ltd-stock-falls-to-52-week-low-of-rs605-3864440",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/VistaPharmaceut_priceRelatedfactors_3864440.png",
        "date": "2026-03-02 10:57:17",
        "description": "Vista Pharmaceuticals Ltd’s stock touched a fresh 52-week low of Rs.6.05 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3845568",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VistaPharmaceut_mojoScore_3845568.png",
        "date": "2026-02-18 10:10:25",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Are Vista Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-vista-pharmaceuticals-ltd-latest-results-good-or-bad-3840314",
        "imagepath": "",
        "date": "2026-02-14 19:37:54",
        "description": "Vista Pharmaceuticals Ltd's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported a net loss of ₹2.32 crores, which reflects a substantial year-on-year decline of 75.76%. This loss is accompanied by an operating margin of -123.97%, a deterioration from the previous year's margin of -58.98%, highlighting ongoing structural weaknesses in its operations.\n\nRevenue for the quarter stood at ₹2.42 crores, which, while showing a sequential improvement of 65.75% from ₹1.46 crores in Q2 FY26, still represents a 5.47% decline compared to ₹2.56 crores in Q3 FY25. This suggests that despite short-term recovery, the company is struggling to maintain consistent revenue growth over the longer term.\n\nThe nine-month performance for FY26 further illustrates the difficulties faced by Vista Pharmaceuticals, with total sales declining by 21.17% to ₹5.40 crores from ₹6.85 crores in..."
      },
      {
        "title": "Vista Pharmaceuticals Q3 FY26: Mounting Losses and Deteriorating Margins Signal Deep Distress",
        "link": "https://www.marketsmojo.com/news/result-analysis/vista-pharmaceuticals-q3-fy26-mounting-losses-and-deteriorating-margins-signal-deep-distress-3839440",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VistaPharmaceut_quaterlyResult_3839440.png",
        "date": "2026-02-14 08:57:52",
        "description": "Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical formulation company, reported deeply troubling Q3 FY26 results that underscore the severe operational and financial distress gripping the organisation. The company posted a net loss of ₹2.32 crores for the quarter ended December 2025, representing a 75.76% deterioration from the ₹1.32 crores loss recorded in Q3 FY25. With a market capitalisation of just ₹45.00 crores, the stock plunged 5.91% following the results announcement, closing at ₹6.85 on February 13, 2026—a mere 4.26% above its 52-week low of ₹6.57."
      },
      {
        "title": "Are Vista Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-vista-pharmaceuticals-ltd-latest-results-good-or-bad-3838025",
        "imagepath": "",
        "date": "2026-02-13 19:40:21",
        "description": "Vista Pharmaceuticals Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹1.46 crores, reflecting a year-on-year decline of 41.37% and a sequential decrease of 3.95% from the previous quarter. This marks the lowest quarterly revenue since Q4 FY24, indicating a sustained deterioration in commercial performance.\n\nThe net loss for the quarter amounted to ₹2.59 crores, which represents a substantial increase in losses compared to ₹1.29 crores in Q1 FY26 and ₹0.97 crores in Q2 FY25. The operating margin plummeted to -235.62%, indicating that operating expenses are more than double the revenue generated, which raises serious concerns about the company's financial viability.\n\nAdditionally, the company's operating profit before depreciation, interest, tax, and other income (PBDIT) showed a record loss of ₹3.44 crores, a dramatic deterioration from..."
      },
      {
        "title": "Vista Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/vista-pharmaceuticals-ltd-is-rated-strong-sell-3824110",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VistaPharmaceut_mojoScore_3824110.png",
        "date": "2026-02-06 10:10:27",
        "description": "Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Vista Pharmaceuticals Ltd Stock Hits 52-Week Low at Rs.6.57",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/vista-pharmaceuticals-ltd-stock-hits-52-week-low-at-rs657-3814289",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VistaPharmaceut_priceRelatedfactors_3814289.png",
        "date": "2026-02-01 10:42:12",
        "description": "Vista Pharmaceuticals Ltd has reached a new 52-week low price of Rs.6.57, marking a significant decline amid ongoing financial pressures and subdued market performance within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 5711,
    "sid": "384463",
    "stock_news_url": "https://www.marketsmojo.com/news/vista-pharmaceuticals-384463"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Un Audited Financial Results For The Quarter Ended 31.12.2025",
      "datetime": "13-Feb-2026",
      "details": "Un audited Financial Results for the quarter ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Results For The Quarter Ended 31.12.2025",
      "datetime": "13-Feb-2026",
      "details": "Results for the quarter ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Update on board meeting",
      "datetime": "05-Feb-2026",
      "details": "The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026 The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.5.71

2026-03-09 11:27:42

Vista Pharmaceuticals Ltd’s stock declined to a fresh 52-week low of Rs.5.71 today, marking a significant downturn amid broader market weakness and company-specific headwinds. The stock underperformed its sector and has now reversed gains seen over the previous three sessions.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-03-05 10:10:20

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 March 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Vista Pharmaceuticals Ltd Stock Falls to 52-Week Low of Rs.6.05

2026-03-02 10:57:17

Vista Pharmaceuticals Ltd’s stock touched a fresh 52-week low of Rs.6.05 today, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics.

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-02-18 10:10:25

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 18 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Are Vista Pharmaceuticals Ltd latest results good or bad?

2026-02-14 19:37:54

Vista Pharmaceuticals Ltd's latest financial results for Q3 FY26 indicate significant operational challenges. The company reported a net loss of ₹2.32 crores, which reflects a substantial year-on-year decline of 75.76%. This loss is accompanied by an operating margin of -123.97%, a deterioration from the previous year's margin of -58.98%, highlighting ongoing structural weaknesses in its operations. Revenue for the quarter stood at ₹2.42 crores, which, while showing a sequential improvement of 65.75% from ₹1.46 crores in Q2 FY26, still represents a 5.47% decline compared to ₹2.56 crores in Q3 FY25. This suggests that despite short-term recovery, the company is struggling to maintain consistent revenue growth over the longer term. The nine-month performance for FY26 further illustrates the difficulties faced by Vista Pharmaceuticals, with total sales declining by 21.17% to ₹5.40 crores from ₹6.85 crores in...

Read full news article

Vista Pharmaceuticals Q3 FY26: Mounting Losses and Deteriorating Margins Signal Deep Distress

2026-02-14 08:57:52

Vista Pharmaceuticals Ltd., a micro-cap pharmaceutical formulation company, reported deeply troubling Q3 FY26 results that underscore the severe operational and financial distress gripping the organisation. The company posted a net loss of ₹2.32 crores for the quarter ended December 2025, representing a 75.76% deterioration from the ₹1.32 crores loss recorded in Q3 FY25. With a market capitalisation of just ₹45.00 crores, the stock plunged 5.91% following the results announcement, closing at ₹6.85 on February 13, 2026—a mere 4.26% above its 52-week low of ₹6.57.

Read full news article

Are Vista Pharmaceuticals Ltd latest results good or bad?

2026-02-13 19:40:21

Vista Pharmaceuticals Ltd's latest financial results for Q2 FY26 reveal significant operational challenges. The company reported net sales of ₹1.46 crores, reflecting a year-on-year decline of 41.37% and a sequential decrease of 3.95% from the previous quarter. This marks the lowest quarterly revenue since Q4 FY24, indicating a sustained deterioration in commercial performance. The net loss for the quarter amounted to ₹2.59 crores, which represents a substantial increase in losses compared to ₹1.29 crores in Q1 FY26 and ₹0.97 crores in Q2 FY25. The operating margin plummeted to -235.62%, indicating that operating expenses are more than double the revenue generated, which raises serious concerns about the company's financial viability. Additionally, the company's operating profit before depreciation, interest, tax, and other income (PBDIT) showed a record loss of ₹3.44 crores, a dramatic deterioration from...

Read full news article

Vista Pharmaceuticals Ltd is Rated Strong Sell

2026-02-06 10:10:27

Vista Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 18 July 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 06 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Vista Pharmaceuticals Ltd Stock Hits 52-Week Low at Rs.6.57

2026-02-01 10:42:12

Vista Pharmaceuticals Ltd has reached a new 52-week low price of Rs.6.57, marking a significant decline amid ongoing financial pressures and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News